Lisdexamfetamine
Indications
| Indication | Approved Population | First Approval | Status |
|---|---|---|---|
| Attention-Deficit/Hyperactivity Disorder (ADHD) | Adults and pediatric patients ≥6 years | 2007 | FDA Approved |
| Moderate to severe Binge Eating Disorder (BED) | Adults only | January 2015 | FDA Approved |
Lisdexamfetamine is a prodrug of dextroamphetamine that occupies a unique position among stimulants for two reasons. First, it is the only stimulant FDA-approved for binge eating disorder (approved January 2015) — no other amphetamine or methylphenidate product carries this indication, and lisdexamfetamine remains the only pharmacotherapy with FDA approval for moderate-to-severe BED in adults. Second, its prodrug pharmacology — requiring hydrolysis by red blood cells to release the active d-amphetamine — provides a smooth, predictable release pattern with reduced abuse liability via non-oral routes. In an FDA-cited intravenous abuse liability study, IV lisdexamfetamine produced lower subjective drug effects than equivalent doses of IV d-amphetamine in patients with a history of stimulant abuse. Despite this, lisdexamfetamine remains a Schedule II controlled substance with full abuse potential when taken orally at supratherapeutic doses.
For ADHD, lisdexamfetamine is one of the principal first-line stimulant options alongside methylphenidate-class agents and other amphetamine products. NICE (UK) positions lisdexamfetamine as a first-line stimulant option in adults. Because of its prodrug pharmacology and once-daily dosing, it is often considered for patients with concerns about diversion, college students, or anyone who would benefit from a tamper-resistant formulation.
Pediatric <6 years: Not recommended. Children ages 4–5 had approximately 44% higher steady-state plasma exposure of dextroamphetamine compared to children 6–11 years at the same dose, with a higher incidence of adverse reactions including weight loss, decreased appetite, insomnia, irritability, and affect lability. This limitation was specifically updated in the September 2025 label revision.
Weight loss: VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. Safety and effectiveness for the treatment of obesity have not been established.
BED in adolescents: Safety and effectiveness have not been established in patients with BED less than 18 years of age.
Treatment-resistant depression (augmentation): Used in some specialist psychiatric and palliative settings; evidence quality low. Lisdexamfetamine has been studied in augmentation trials for major depressive disorder but did not consistently meet primary endpoints in pivotal studies — no FDA approval for depression.
Cancer-related fatigue: Some palliative care use; evidence quality low. Methylphenidate has more evidence in this setting.
Cognitive symptoms in traumatic brain injury and post-stroke recovery: Limited evidence; methylphenidate generally preferred in rehabilitation settings.
Off-label use as a “study aid” or cognitive enhancer in non-ADHD individuals is not supported by clinical evidence and is associated with substantial misuse risk; this practice should be actively discouraged.
Dosing
Lisdexamfetamine is administered orally once daily in the morning with or without food. Afternoon doses must be avoided because of insomnia risk. Capsules can be swallowed whole or opened and the contents mixed with yogurt, water, or orange juice (mixture must be consumed immediately and not stored). Chewable tablets must be chewed thoroughly before swallowing. Capsules and chewable tablets are interchangeable on a unit-per-unit (mg-per-mg) basis. A single dose should not be divided, and patients should not take less than one capsule or chewable tablet per day.
By Indication and Population
| Clinical Scenario | Starting Dose | Titration | Recommended Range | Maximum | Notes |
|---|---|---|---|---|---|
| ADHD — adults and pediatric (≥6 y) | 30 mg PO once daily (morning) | 10 mg or 20 mg increments at approximately weekly intervals | 30–70 mg/day | 70 mg/day | Same dosing for adults and children ≥6 years per current FDA label Take in morning; avoid afternoon doses |
| BED — adults only | 30 mg PO once daily (morning) | 20 mg increments at approximately weekly intervals | 50–70 mg/day (target range) | 70 mg/day | Discontinue if binge eating does not improve Not approved for BED in adolescents/children |
| Severe renal impairment (GFR 15 to <30 mL/min/1.73 m²) | Same starting dose; titrate as tolerated | 50 mg/day | Reduced clearance requires lower maximum | ||
| End-stage renal disease (GFR <15 mL/min/1.73 m²) | Lower exposure tolerance | 30 mg/day | Lisdexamfetamine and d-amphetamine are NOT dialysable | ||
| Switching between capsules and chewable tablets | Same total daily dose; mg-per-mg interchange | Same as current | No re-titration needed; chewable tablets max 60 mg (no 70 mg chewable strength) | ||
| CYP2D6 inhibitor co-administration (e.g., paroxetine, fluoxetine, bupropion, quinidine, terbinafine) | Initiate with lower dose; monitor for serotonin syndrome | Individualised | Increases dextroamphetamine exposure | ||
| Alkalinising agent co-administration (e.g., sodium bicarbonate) | Avoid concurrent use; counsel about OTC antacids | Adjust per label | Increases amphetamine blood levels | ||
Special Populations
- Pediatric <6 years: Not recommended. The 09/2025 label update explicitly addressed higher exposure (~44% higher steady-state dextroamphetamine in 4–5 year-olds vs 6–11 year-olds at the same dose) and a higher incidence of adverse reactions including weight loss, decreased appetite, insomnia, irritability, and affect lability.
- Pediatric BED <18 years: Safety and efficacy not established. The BED indication is restricted to adults.
- Geriatric (≥65 years): Insufficient data in clinical trials to determine differential response. Start at the low end of the dosing range, considering greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease.
- Renal impairment: Severe (GFR 15 to <30 mL/min/1.73 m²) — maximum 50 mg/day. ESRD (GFR <15 mL/min/1.73 m²) — maximum 30 mg/day. Lisdexamfetamine and d-amphetamine are not dialysable.
- Hepatic impairment: Not formally studied. Because the prodrug is hydrolysed by red blood cells (not by CYP enzymes) to release dextroamphetamine, hepatic dysfunction may have less impact on lisdexamfetamine exposure than for parent amphetamine products. Caution still warranted.
- Pregnancy: Available data from published literature and postmarketing reports are not sufficient to inform a drug-associated risk. Animal reproduction studies showed no embryo-fetal effects with lisdexamfetamine in rats and rabbits during organogenesis at doses up to 5.5× and 33× the MRHD respectively. Amphetamines may cause vasoconstriction and decreased placental perfusion; uterine contractions may be stimulated. National Pregnancy Registry for Psychostimulants: 1-866-961-2388.
- Lactation: Amphetamine is present in human milk at relative infant doses of 2–13.8% with milk-to-plasma ratios of 1.9–7.5. The FDA label specifically advises that breastfeeding is not recommended during VYVANSE treatment because of the potential for serious adverse reactions in nursing infants (cardiovascular reactions, BP/HR increases, growth suppression, peripheral vasculopathy).
Unlike Adderall, lisdexamfetamine does not have an immediate-release formulation, and the dosing label is exclusively once-daily morning. This is because the prodrug must be hydrolysed by red blood cells to release active d-amphetamine — a rate-limiting step that produces a smooth, predictable plasma curve. Per Ermer et al. (2016), the therapeutic action of lisdexamfetamine extends to at least 13 hours post-dose in children and 14 hours post-dose in adults. Splitting doses or attempting twice-daily dosing offers no PK advantage and increases insomnia risk. If a patient needs longer coverage than lisdexamfetamine provides, options include switching to triple-bead amphetamine (Mydayis, ≥13 years) — but this requires careful clinical judgement and increased monitoring.
Before initiating lisdexamfetamine, the FDA labelling requires: (1) careful cardiac history including family history of sudden cardiac death or ventricular arrhythmia, plus a physical examination; (2) family history and clinical evaluation for tics or Tourette’s syndrome; (3) screening for risk factors for a manic episode (history of depression, family history of bipolar disorder or suicide); (4) baseline blood pressure, heart rate, height and weight; and (5) assessment of risk for abuse, misuse, and addiction. Document each step in the medical record.
Pharmacology
Mechanism of Action
Lisdexamfetamine is a prodrug of dextroamphetamine, formed by covalent linkage of the essential amino acid L-lysine to d-amphetamine via a peptide bond. The intact prodrug is pharmacologically inactive. After oral absorption, lisdexamfetamine is hydrolysed by red blood cells to release the active d-amphetamine and L-lysine. This hydrolysis is the rate-limiting step that controls the appearance of d-amphetamine in plasma — not gastric emptying, GI absorption, or cytochrome metabolism.
Once released, d-amphetamine exerts its pharmacological effects in the same way as parent amphetamine: blocking the reuptake of norepinephrine and dopamine into presynaptic neurons and increasing release of these monoamines into the extraneuronal space. Amphetamines also affect the serotonergic system, which underlies the labelled risk of serotonin syndrome. The FDA label states that the precise mode of therapeutic action in ADHD is not known.
Implications of prodrug pharmacology:
- Smoother PK curve: The hydrolysis rate-limiting step produces a more gradual rise and fall in plasma d-amphetamine than direct oral d-amphetamine, with reduced peak-to-trough ratio and lower inter- and intra-individual variability in exposure (per Ermer et al., 2016).
- Reduced abuse liability via non-oral routes: Crushing, snorting, or injecting lisdexamfetamine does not bypass the hydrolysis step. In an FDA-cited abuse liability study (Jasinski & Krishnan, 2009), IV administration of 50 mg lisdexamfetamine produced lower subjective “drug liking” effects than IV 20 mg d-amphetamine in patients with a history of stimulant abuse. This is one reason lisdexamfetamine is sometimes preferred in patients with diversion concerns. However, oral lisdexamfetamine at supratherapeutic doses can still produce significant abuse, and the boxed warning applies fully.
- Limited drug-interaction profile via metabolism: Lisdexamfetamine is not metabolised by cytochrome P450 enzymes. The current FDA label explicitly states no dose adjustment is needed when co-administered with substrates of CYP1A2, CYP2D6, CYP2C19, or CYP3A4.
- No food effect on AUC/Cmax: Food prolongs Tmax of d-amphetamine by approximately 1 hour (from 3.8 h fasted to 4.7 h after high-fat meal) but does not alter AUC or Cmax.
- No accumulation at steady state with once-daily dosing.
Cardiovascular pharmacodynamics: amphetamines (including released d-amphetamine) produce small mean increases in heart rate (approximately 3–6 bpm) and blood pressure (approximately 2–4 mmHg) at therapeutic doses; some patients show larger increases.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Lisdexamfetamine is rapidly absorbed from the GI tract; d-amphetamine Tmax ~3.8 h fasted, ~4.7 h after high-fat meal, ~4.2 h with yogurt; food prolongs Tmax by ~1 h but does not affect AUC or Cmax | Take with or without food; capsule contents may be mixed with water, yogurt, or orange juice; chewable tablets must be chewed thoroughly |
| Distribution | Wide tissue distribution; d-amphetamine readily crosses blood-brain barrier; specific Vd not stated in current US PI | Onset of clinical effects begins within approximately 1.5–2 hours of administration based on laboratory school study data |
| Metabolism | Lisdexamfetamine is hydrolysed by red blood cells to release d-amphetamine and L-lysine; substantial hydrolysis occurs even at low haematocrit (33% of normal) per in vitro data; lisdexamfetamine is NOT metabolised by cytochrome P450 enzymes; the released d-amphetamine then undergoes hepatic oxidation (with partial CYP2D6 contribution) and conjugation | Few clinically meaningful drug interactions via metabolism; no dose adjustment needed for CYP1A2, CYP2D6, CYP2C19, or CYP3A4 substrates |
| Elimination | Renal excretion of d-amphetamine is highly pH-dependent (pKa 9.9 — alkaline urine reduces elimination, acidic urine increases it); elimination half-life of d-amphetamine ~10 hours (consistent with parent amphetamine PK); no accumulation with once-daily dosing; lisdexamfetamine and d-amphetamine are not dialysable | Urinary alkalinising agents (e.g., sodium bicarbonate) and acidifying agents (e.g., ascorbic acid) significantly alter exposure; severe renal impairment requires dose reduction; ESRD requires further reduction |
Clinical duration: A single morning dose of lisdexamfetamine provides therapeutic action up to approximately 13 hours in children and 14 hours in adults (Ermer et al., 2016) — generally longer than Adderall XR’s typical coverage and shorter than Mydayis.
Side Effects
Lisdexamfetamine has the typical stimulant adverse-effect profile dominated by appetite suppression, insomnia, dry mouth, weight loss, and small cardiovascular changes. The adverse-event profile is broadly similar to that of mixed amphetamine salts. All quantitative incidence data below are taken directly from the Vyvanse FDA prescribing information clinical trial tables (Tables 1, 2, 3, 4; revised 09/2025).
| Adverse Effect | Population / Incidence | Clinical Note |
|---|---|---|
| Decreased appetite | 39% (children 6–12), 34% (adolescents 13–17), 27% (adults ADHD) vs 4%, 3%, 2% placebo respectively | Most common adverse effect; dose-related; encourage front-loaded breakfast and calorie-dense evening intake |
| Dry mouth | 26% (adults ADHD), 36% (adults BED) vs 3%, 7% placebo respectively; 5% in children 6–12 (vs 0% placebo) | Most prominent in adults; encourage hydration; sugar-free gum or saliva substitutes; dental review for prolonged use |
| Insomnia | 22% (children 6–12), 13% (adolescents 13–17), 27% (adults ADHD), 20% (adults BED) vs 3%, 4%, 8%, 8% placebo respectively | Avoid late dosing; assess sleep hygiene; if persistent consider lower dose |
| Upper abdominal pain (children 6–12) | 12% (children) vs 6% placebo | Usually mild and transient; take with food |
| Irritability (children 6–12) | 10% (children) vs 0% placebo | Often dose-related; consider dose reduction; evaluate for end-of-dose rebound |
| Adverse Effect | Population / Incidence | Clinical Note |
|---|---|---|
| Vomiting (children 6–12) | 9% vs 4% placebo | Take with food; usually transient |
| Weight decreased | 9% (children 6–12), 9% (adolescents 13–17), 3% (adults ADHD), 4% (adults BED) vs 1%, 0%, 0%, 0% placebo respectively | Plot growth at every visit in children; dose-related — see weight loss data below |
| Nausea | 6% (children 6–12), 7% (adults ADHD) vs 3%, 0% placebo | Take with food |
| Anxiety (adults) | 6% (adults ADHD), 5% (adults BED) vs 0%, 1% placebo | Often dose-related; can lead to discontinuation |
| Diarrhea (adults) | 7% (adults ADHD), 4% (adults BED) vs 0%, 2% placebo | Generally mild; assess hydration |
| Increased heart rate (adults) | 7% (adults BED), 2% (adults ADHD) vs 1%, 0% placebo | Mean HR increase 3–6 bpm; some patients larger; monitor pulse at every visit |
| Constipation (adults BED) | 6% (adults BED) vs 1% placebo | Notable for BED population; encourage fluids and fibre |
| Feeling jittery (adults) | 6% (adults BED), 4% (adults ADHD) vs 1%, 0% placebo | Often dose-related |
| Dizziness (children 6–12) | 5% (children) vs 0% placebo | Caution with active play; evaluate for hypotension |
| Anorexia (distinguished from “decreased appetite”) | 2% (children), 2% (adolescents), 5% (adults ADHD) vs 0%, 0%, 0% placebo | Dose-related; manage with calorie-dense foods at peak appetite times |
| Hyperhidrosis (adults) | 4% (adults BED), 3% (adults ADHD) vs 0%, 0% placebo | Sympathomimetic effect; usually tolerable |
| Affect lability (children 6–12) | 3% (children) vs 0% placebo | Higher rates seen in 4–5 year-olds (off-label) — one reason for the <6 years recommendation |
| Rash (children 6–12) | 3% (children) vs 0% placebo | Usually mild; evaluate for serious cutaneous reactions if extensive |
| Tic (children 6–12) | 2% (children) vs 0% placebo | Pre-existing tics or family history are warning signs; monitor closely; discontinue if worsening |
| Tremor (adolescents, adults) | 2% (adolescents), 2% (adults ADHD) vs 0%, 0% placebo | Sympathomimetic; usually tolerable |
| Palpitations (adolescents, adults) | 2% (adolescents), 2% (adults ADHD) vs 1%, 0% placebo | Investigate if persistent; ECG if suspected arrhythmia |
| Erectile dysfunction (adult males) | 2.6% (adult males) vs 0% placebo | Sometimes dose-limiting; consider dose reduction |
| Decreased libido (adults) | 1.4% (adults) vs 0% placebo | Often improves with dose reduction |
| Increased blood pressure | 3% (adults ADHD) vs 0% placebo; mean rise 2–4 mmHg overall | Some patients larger increases; routine monitoring captures this early |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Substance use disorder, dependence, overdose, death (boxed warning) | Risk variable; markedly elevated with non-medical use | Any time during therapy; risk rises with high-dose oral use | Pre-treatment risk screen; safe storage; monitor throughout treatment; consider gradual taper after prolonged use; prodrug pharmacology reduces but does not eliminate abuse risk |
| Sudden death, stroke, myocardial infarction (in patients with serious cardiac disease) | Rare post-marketing reports at therapeutic ADHD doses | Any time; pediatric cases reported in those with structural heart disease | Avoid in known structural cardiac abnormality, cardiomyopathy, serious arrhythmia, or coronary disease; investigate exertional chest pain, syncope, arrhythmia |
| New psychotic or manic symptoms (hallucinations, delusional thinking, mania) | ~0.1% pooled placebo-controlled trials in patients without prior psychotic history | Days to weeks after initiation or dose increase | Consider discontinuation; evaluate for underlying bipolar disorder; do not restart without specialist input |
| Serotonin syndrome (with serotonergic agents or CYP2D6 inhibitors) | Rare; labelled warning (Section 5.7 in current PI) | Hours to days after combining with serotonergic drug or starting CYP2D6 inhibitor | Discontinue both agents immediately; supportive care; CYP2D6 inhibitors increase exposure to released d-amphetamine |
| Long-term suppression of growth (pediatric) | Mean weight change −0.9 to −2.5 lbs (children 6–12, doses 30/50/70 mg) and −2.7 to −4.8 lbs (adolescents) vs +1 lb / +2 lbs placebo gain in 4-week trials; 12-month percentile change −13.4 in children | Weight changes detectable within 4 weeks; cumulative over months–years | Plot height/weight at every visit; if not tracking expected curve, interrupt treatment or consider drug holidays |
| Peripheral vasculopathy / Raynaud’s phenomenon | Uncommon post-marketing; can include digital ulceration / soft-tissue breakdown | Any time during treatment; intermittent symptoms | Examine fingers/toes at follow-up; refer to rheumatology if signs of vasculopathy; reduce dose or discontinue if symptomatic |
| Severe cutaneous reactions (Stevens-Johnson syndrome) | Very rare post-marketing reports | Any time; usually within first weeks of treatment | Immediate discontinuation; emergency dermatology evaluation; permanent contraindication to amphetamines |
| Hypersensitivity (anaphylaxis, angioedema, urticaria) | Rare | Minutes to days after dosing | Permanent discontinuation; emergency care if airway involved; document allergy |
| Cardiomyopathy (chronic use) | Isolated reports post-marketing | Long-term cumulative | Investigate any new exertional symptoms or echocardiographic changes; consider discontinuation |
| Eosinophilic hepatitis | Rare post-marketing reports | Any time | Discontinue if liver enzyme abnormalities and eosinophilia develop; specialist evaluation |
| Priapism (frequent or prolonged erections) | Rare listed in post-marketing experience | After some time on therapy; may occur during dose changes | Immediate medical attention — irreversible damage possible without prompt urology evaluation |
| Seizures | Rare post-marketing; amphetamines may lower seizure threshold | Any time; risk highest in those with prior seizure history | Discontinue if seizure occurs; use cautiously in seizure disorder |
| Rhabdomyolysis | Rare post-marketing; especially with overdose or strenuous exertion | Acute | Discontinue; emergency care with hydration and CK monitoring |
Weight Loss Data — by Dose
| Population | Dose 30 mg | Dose 50 mg | Dose 70 mg | Placebo |
|---|---|---|---|---|
| Children ages 6–12 (4-week) | −0.9 lbs | −1.9 lbs | −2.5 lbs | +1.0 lb |
| Adolescents ages 13–17 (4-week) | −2.7 lbs | −4.3 lbs | −4.8 lbs | +2.0 lbs |
| Adults ADHD (4-week, final dose) | −2.8 lbs | −3.1 lbs | −4.3 lbs | +0.5 lbs |
| Children 6–12 (12-month follow-up) | Mean change in age- and sex-normalized weight percentile: −13.4 (from 60.9 to 47.2 over 12 months) | — | ||
The 6% adult ADHD discontinuation rate in the Vyvanse trial appears lower than the 12% rate reported in the Adderall XR adult ADHD trial (4-week, doses up to 60 mg). However, cross-trial comparisons are not straightforward because of different dose ranges, study designs, and patient populations. The lower observed rate may partly reflect the smoother PK profile produced by lisdexamfetamine’s prodrug release. Clinically, lisdexamfetamine is often perceived to be better tolerated than IR amphetamine, particularly in adults sensitive to peak-related anxiety or jitteriness.
Drug Interactions
Lisdexamfetamine has a more limited drug-interaction profile than parent amphetamine because the prodrug itself is hydrolysed by red blood cells rather than metabolised by cytochrome enzymes. The current Vyvanse PI Table 5 lists six categories of clinically important interactions: monoamine oxidase inhibitors, serotonergic drugs, CYP2D6 inhibitors, alkalinising agents, acidifying agents, and tricyclic antidepressants. Notably, the FDA label specifically lists categories of drugs with no clinically important interactions: guanfacine, venlafaxine, omeprazole, and CYP1A2/2D6/2C19/3A4 substrates — a useful clinical fact when managing complex polypharmacy.
The current Vyvanse label specifically states that no dose adjustment of Vyvanse is necessary when co-administered with: guanfacine, venlafaxine, or omeprazole. In addition, no dose adjustment is needed for substrates of the major CYP enzymes — including theophylline, duloxetine, melatonin (CYP1A2); atomoxetine, desipramine, venlafaxine (CYP2D6); omeprazole, lansoprazole, clobazam (CYP2C19); midazolam, pimozide, simvastatin (CYP3A4). This is because lisdexamfetamine itself is hydrolysed by red blood cells, not by CYP enzymes, and the released d-amphetamine produces only minor inhibition of CYP enzymes at therapeutic doses. This is a clinically useful difference from many other CNS-active medications.
Monitoring
Monitoring lisdexamfetamine therapy is structured around five pillars: cardiovascular vital signs, growth (in children), psychiatric tolerability, abuse/misuse surveillance, and (for BED) clinical response — discontinuing if binge eating does not improve. The goal is early detection of dose-related side effects and prevention of diversion or misuse.
-
Blood pressure and heart rate
Baseline, then at every dose change and every routine visit (≥3-monthly)
Routine Mean expected rise: BP 2–4 mmHg, HR 3–6 bpm. Sustained BP >130/80 in adults or >95th centile in children, or HR >100 bpm sustained at rest, warrants dose reduction or alternative therapy. -
Height and weight (pediatric)
Every 3–6 months; plot on growth chart
Routine Pediatric trial data show dose-related weight loss within 4 weeks, and 12-month follow-up shows mean weight percentile decrease of 13.4 in consistently medicated children. Watch for crossing percentiles downward. Consider drug holidays or treatment interruption if growth deviates. -
Psychiatric symptom screen
Every visit
Routine Screen for new mania, psychosis, agitation, suicidal ideation, mood lability, and worsening of pre-existing psychiatric conditions. Document family history of bipolar disorder at baseline. -
Abuse and diversion screening
At each refill; PDMP query as required by state
Routine Although prodrug pharmacology reduces non-oral abuse liability, oral lisdexamfetamine remains highly abusable. Assess for early refill requests, lost prescriptions, multiple-prescriber pattern, and concerning behaviour. Confirm safe storage at home. -
BED response (BED indication only)
At each visit; consider weekly binge-day count
Routine FDA label specifically recommends discontinuing Vyvanse if binge eating does not improve. Combine with cognitive behavioural therapy where possible. -
Sleep and appetite
Every visit
Routine Specific questioning about sleep onset latency, total sleep time, and breakfast/evening intake. These data drive dose adjustment decisions. -
Tic/Tourette’s surveillance
Baseline and every visit
Routine New or worsening motor/verbal tics may emerge; assess at each visit; discontinuation considered if clinically significant. -
Serotonin syndrome surveillance
When combined with any serotonergic agent or CYP2D6 inhibitor
Trigger-based Counsel about agitation, hyperthermia, clonus, hyperreflexia, autonomic instability. Initiate Vyvanse at a lower dose when adding to existing serotonergic regimen. -
Renal function
Annually or as clinically indicated
Routine Vyvanse requires dose reduction in severe renal impairment (max 50 mg/day) and ESRD (max 30 mg/day). Re-evaluate eGFR if comorbidities arise. -
Digital examination (Raynaud’s screen)
Baseline, then on patient report
Trigger-based Examine fingers and toes for colour change, ulceration, or coolness. Refer to rheumatology if signs develop. Discontinue or switch agent if vasculopathy progresses. -
ECG / cardiology referral
Only when cardiac risk factors or symptoms identified
Trigger-based Routine baseline ECG is not mandated by FDA labelling but is reasonable when family history suggests inherited arrhythmia (e.g., long QT, HCM) or in symptomatic patients. Investigate exertional chest pain, syncope, or palpitations promptly. -
Treatment continuation review
Annually
Routine Periodically reassess ongoing need for stimulant therapy. For BED, the label is explicit: discontinue if binge eating does not improve. Consider planned treatment interruptions or holidays where clinically reasonable.
The single highest-yield monitoring intervention is documenting blood pressure, heart rate, height and weight at every visit, plotted on a growth chart for pediatric patients. Combined with a brief psychiatric, sleep, appetite, and abuse-risk screen — and, for BED, an objective measure of binge frequency — this five-minute review captures the major safety and efficacy signals that the FDA boxed warning and labelled precautions all centre on.
Contraindications & Cautions
Absolute Contraindications
- Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or use within 14 days of MAOI discontinuation — this includes the antibiotic linezolid and intravenous methylene blue. Risk of hypertensive crisis, stroke, MI, aortic dissection, and death.
- Known hypersensitivity to amphetamine products or other components of Vyvanse — including prior anaphylaxis, angioedema, urticaria, or Stevens-Johnson syndrome (all reported in postmarketing experience).
Relative Contraindications (Specialist Input Recommended)
- Known structural cardiac abnormalities (e.g., hypertrophic cardiomyopathy), cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease — sudden death has been reported at therapeutic ADHD doses; cardiology assessment required before any consideration of use.
- Active or recent substance use disorder — although prodrug pharmacology reduces non-oral abuse liability, oral lisdexamfetamine has full Schedule II abuse potential. Use only under specialist supervision; non-stimulant alternatives (atomoxetine, viloxazine, guanfacine ER, clonidine ER) should be considered first.
- Pre-existing psychotic disorder — symptoms may be exacerbated; co-management with psychiatry essential.
- Bipolar disorder, especially without mood stabiliser cover — risk of mania induction; do not initiate without psychiatric input and adequate mood stabilisation.
- Pediatric <6 years — not recommended per current FDA label (revised 09/2025). Children 4–5 years had ~44% higher dextroamphetamine exposure and higher rates of weight loss, decreased appetite, insomnia, irritability, and affect lability.
- Pediatric <18 years for BED indication — not approved; safety and efficacy not established.
- Pregnancy — limited human data; amphetamines cause vasoconstriction and may decrease placental perfusion; uterine contractions can be stimulated; use only when benefits clearly outweigh risks. Encourage National Pregnancy Registry for Psychostimulants enrolment (1-866-961-2388).
- Lactation — the FDA label specifically advises against breastfeeding during Vyvanse therapy. RID 2–13.8% of maternal weight-adjusted dose.
- Severe renal impairment and ESRD — dose reductions required (max 50 mg/day in severe impairment, 30 mg/day in ESRD); not dialysable.
- Pre-existing peripheral vasculopathy or Raynaud’s phenomenon with ischaemic complications — risk of digital ulceration; specialist input recommended before initiation.
Use with Caution
- Pre-existing hypertension or tachyarrhythmia — small but real BP and HR increases; ensure stable control before initiation; monitor closely.
- History of motor or verbal tics, or family history of Tourette’s syndrome — may emerge or worsen; assess at every visit.
- History of seizure disorder or EEG abnormalities — amphetamines may lower the seizure threshold; ensure good baseline seizure control before initiation; discontinue if seizure occurs.
- Concurrent use of serotonergic medications or CYP2D6 inhibitors — increased risk of serotonin syndrome; initiate at lower doses with monitoring.
- Concurrent acidifying or alkalinising agents — may significantly alter dextroamphetamine exposure; counsel about OTC antacids and high-dose vitamin C.
- Pediatric patients on year-round stimulant therapy — monitor growth; consider drug holidays.
- Older adults (≥65 years) — limited safety data; cardiovascular comorbidity is more common; start at the lowest available dose.
- Patients with depression, anxiety, or suicidal ideation — mood worsening or new psychiatric symptoms have been reported; close monitoring and integrated mental health management required.
- BED patients without response after adequate trial — the FDA label explicitly directs discontinuation if binge eating does not improve.
Vyvanse has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Vyvanse, can result in overdose and death. Risk is increased with higher doses or with unapproved methods of administration such as snorting or injection.
Pre-treatment: Assess each patient’s individual risk for abuse, misuse, and addiction before prescribing. Educate patients and their families about these risks, the importance of safe (preferably locked) storage, and proper disposal of unused medication.
During treatment: Reassess each patient’s risk at each visit and frequently monitor for signs and symptoms of abuse, misuse, and addiction. Maintain careful prescription records and check the state Prescription Drug Monitoring Program where available. Counsel patients explicitly: never share medication, never alter the route of administration, and never increase the dose without prescriber agreement.
Editorial note on prodrug pharmacology: Although the FDA boxed warning text does not address it specifically, lisdexamfetamine’s prodrug structure produces less subjective drug effect when administered IV than equivalent doses of d-amphetamine (per Jasinski & Krishnan, 2009). This reduces but does not eliminate abuse potential. Oral abuse at supratherapeutic doses remains a significant risk and the boxed warning applies fully.
Discontinuation: Vyvanse may produce physical dependence after prolonged use. Withdrawal symptoms can include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor changes. Consider gradual taper rather than abrupt cessation after long-term use.
Patient Counselling
Purpose of Therapy
Vyvanse is a stimulant prescription medicine used to treat attention-deficit/hyperactivity disorder (ADHD) in adults and children aged 6 and older, and moderate-to-severe binge eating disorder (BED) in adults. In ADHD, this medicine can help improve attention, reduce impulsivity, and reduce hyperactivity. In BED, it can reduce the number of binge eating days. Vyvanse works best when combined with non-medication strategies — for ADHD, that means behavioural strategies, school or workplace accommodations, sleep hygiene, exercise, and (where appropriate) parent or family training. For BED, cognitive behavioural therapy and structured eating support remain important. The medicine is not a cure for either condition; it manages symptoms while it is in your system. Vyvanse is not approved for, and should never be used for, weight loss.
How to Take
Vyvanse is taken once a day in the morning, with or without food. Do not take it in the afternoon or evening — it can cause trouble sleeping. Capsules can be swallowed whole, or you can open the capsule and stir the contents into a small amount of yogurt, water, or orange juice. If you do this, drink or eat the whole mixture right away — do not save it for later. Chewable tablets must be chewed thoroughly before swallowing. Do not split a dose. Do not take less than one whole capsule or chewable tablet per day.
Sources
- U.S. Food and Drug Administration. VYVANSE (lisdexamfetamine dimesylate) capsules and chewable tablets, CII — Prescribing Information. Takeda Pharmaceuticals. Revised September 2025. Reference ID 5664030. accessdata.fda.gov Most recent FDA-approved label for Vyvanse; primary source for all quantitative adverse-event incidence data, drug interaction Table 5, dosing recommendations, weight loss data, and labelled warnings used in this monograph. Recent major changes (09/2025): Indications and Usage (1), Warnings and Precautions (5.5).
- U.S. Food and Drug Administration. FDA expands uses of Vyvanse to treat binge-eating disorder. FDA News Release, January 30, 2015. fda.gov Press release accompanying the January 2015 FDA approval of Vyvanse for moderate-to-severe binge eating disorder in adults — the first and only FDA-approved pharmacotherapy for BED.
- U.S. Food and Drug Administration. Drug Safety Communication: Risk of weight loss in children younger than 6 years taking extended-release stimulants for ADHD. June 30, 2025. fda.gov Recent FDA safety communication informing labelling updates for extended-release stimulants in patients younger than 6 years; relevant context for the 09/2025 Vyvanse limitation of use in children <6 years.
- McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–246. doi: 10.1001/jamapsychiatry.2014.2162 Pivotal phase 3 trial of lisdexamfetamine in adult BED; supported FDA approval. Demonstrated significant reduction in binge eating days/week vs placebo.
- McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251–1260. doi: 10.1038/npp.2015.275 Pooled analysis of the two pivotal 12-week BED trials at lisdexamfetamine 50 and 70 mg/day; both studies favoured LDX over placebo on the primary endpoint.
- Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):903–910. doi: 10.1001/jamapsychiatry.2017.1889 Long-term randomized withdrawal study showing lisdexamfetamine markedly reduced relapse risk in BED.
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi: 10.1016/S2215-0366(18)30269-4 Network meta-analysis comparing ADHD medications across age groups; methylphenidate is favoured in children/adolescents while amphetamines (including lisdexamfetamine) are favoured in adults on the efficacy/tolerability balance.
- Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–1904. doi: 10.1056/NEJMoa1110212 Large cohort study (~1.2 million patients aged 2–24) showing no significant increase in serious cardiovascular events with stimulant ADHD medications including amphetamines.
- Wolraich ML, Hagan JF Jr, Allan C, et al; Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. doi: 10.1542/peds.2019-2528 American Academy of Pediatrics guideline; supports stimulants (methylphenidate or amphetamines, including lisdexamfetamine) as first-line pharmacotherapy for ADHD in children ≥6 years.
- National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. nice.org.uk/guidance/ng87 UK national guideline; positions lisdexamfetamine and methylphenidate as first-line stimulant options in adults with ADHD.
- Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36(5):341–356. doi: 10.1007/s40261-015-0354-y Detailed open-access review of lisdexamfetamine’s prodrug PK/PD profile, including red blood cell hydrolysis kinetics and the relationship between exposure and clinical duration of effect (up to 13 hours in children, 14 hours in adults).
- Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present — a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479–496. doi: 10.1177/0269881113482532 Comprehensive review of amphetamine pharmacology including detailed coverage of lisdexamfetamine’s prodrug pharmacology and reduced abuse liability profile.
- Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410–418. doi: 10.1177/0269881108093841 FDA-cited IV abuse liability study showing IV lisdexamfetamine produces lower subjective drug effects than equivalent doses of IV d-amphetamine in stimulant abusers.
- Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018;8(8):CD007813. doi: 10.1002/14651858.CD007813.pub3 Cochrane systematic review including lisdexamfetamine; demonstrated short-term efficacy in adult ADHD with low to very low certainty of evidence.
- Huybrechts KF, Bröms G, Christensen LB, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations. JAMA Psychiatry. 2018;75(2):167–175. doi: 10.1001/jamapsychiatry.2017.3644 Large multinational cohort study evaluating birth defect risk with stimulant exposure during pregnancy.
- Heo YA, Duggan ST. Lisdexamfetamine: a review in binge eating disorder. CNS Drugs. 2017;31(11):1015–1022. doi: 10.1007/s40263-017-0477-1 Comprehensive review of lisdexamfetamine for BED, covering efficacy, safety, dosing, and clinical positioning.